Blonanserin is a D2/5-HT2 receptor antagonist; atypical antipsychotic.
Features and Benefits
This compound was developed by Dainippon Sumitomo. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Journal of chromatographic science, 50(8), 727-732 (2012-05-19)
Blonanserin is a novel atypical antipsychotic agent for the treatment of schizophrenia. Ethyl alcohol, isopropyl alcohol and toluene are utilized in the synthesis route of this bulk drug. A new validated gas chromatographic (GC) method for the simultaneous determination of
Psychiatry and clinical neurosciences, 65(4), 389-391 (2011-05-17)
The purpose of the present study was to provide preliminary data on the usefulness and safety of blonanserin for patients with delirium in the intensive care unit (ICU). The charts of 32 consecutive patients with delirium in the ICU were
Quetiapine-induced insulin resistance after switching from blonanserin despite a loss in both bodyweight and waist circumference.
Yutaro Suzuki et al.
Psychiatry and clinical neurosciences, 66(6), 534-535 (2012-10-17)
